Jiangsu Vcare's Class 1 Innovative Drug VC005 Tablets Receives Clinical Trial Approval
Published Time:
2021-08-16 17:38
Source:
In August 2021, VC005 tablets, an innovative drug developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received clinical trial approval from the NMPA for the indication of inflammatory bowel disease (IBD), with clinical trials set to begin shortly.
VC005 tablets is a novel, highly selective JAK1 inhibitor independently developed by Jiangsu Vcare. It effectively inhibits inflammatory targets such as TYK2 while simultaneously suppressing immune cell-mediated cytotoxicity and immune responses. It exhibits weaker inhibitory activity against JAK2 and JAK3, demonstrating favorable compound selectivity.
The JAK-STAT signaling pathway plays a crucial role in the pathogenesis of diseases like IBD. Marketed oral JAK inhibitors, due to their lower selectivity, inhibit JAK1 while also affecting targets like JAK2 and JAK3. This has led to the clinical manifestation of severe adverse reactions, including anemia, infections, dyslipidemia, and malignancies, prompting the FDA to issue boxed warnings. As safety concerns regarding JAK inhibitors have been frequently reported, regulatory agencies have become increasingly cautious regarding the expansion of indications and the review of new drug applications for this class. Since the first half of 2021, the FDA has repeatedly delayed review decisions for JAK inhibitors, drawing significant attention from the biopharmaceutical industry.
The development of VC005 tablets is based on a differentiated strategy, specifically addressing the above-mentioned issues from the initiation and design stages of the project. Preclinical studies have confirmed that compared to drugs targeting the same pathway, VC005 exhibits a lower effective dose, higher tolerated dose, and fewer side effects in animal models, suggesting potential dual advantages in both safety and efficacy. It holds promise to become a globally leading therapeutic option for autoimmune and inflammatory diseases.
Related News
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
03
2025
/
07
Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.
View Details
30
2025
/
05
Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.
View Details
21
2025
/
05
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.
View Details
09
2025
/
05
On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn